Eiger BioPharmaceuticals to Participate in Upcoming Investor Conferences

PALO ALTO, Calif., Nov. 6, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for orphan diseases, announced today that David Cory, President and CEO of Eiger, will participate and present in three upcoming investor conferences.

• Jefferies 2017 London Healthcare Conference, November 15-16, 2017 at Waldorf Hilton London. Eiger will host one-on-one meetings.
• 29^th Annual Piper Jaffray Healthcare Conference, November 29, 2017,      
  Fireside Chat at 3:00 pm ET at Lotte New York Palace Hotel, NYC.                              
  Eiger will host one-on-one meetings.
• Oppenheimer Rare Disease Day, December 5, 2017 at Sofitel New York, NYC.   
  Eiger will host one-on-one meetings.

A live webcast of the Fireside chat will be available on the Eiger BioPharmaceuticals website at www.eigerbio.com under the "Investors" tab.  A replay of the webcast will be available approximately one hour following the completion of the live event.

About Eiger
Eiger is a clinical-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for orphan diseases.  We are committed to realizing the full value of promising research from academic research and collaborations, independent investigators, and the pharmaceutical industry to efficiently translate programs into the clinic.  Through the repurposing of drugs for orphan diseases, our mission is to systematically reduce the time and cost of the drug development process to more rapidly deliver important medicines to patients.  For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.

Investors: Ingrid Choong, PhD
Eiger BioPharmaceuticals, Inc.
1-650-619-6115, ichoong@eigerbio.com

View original content with multimedia:http://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-to-participate-in-upcoming-investor-conferences-300549227.html

SOURCE Eiger BioPharmaceuticals, Inc.